Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Amicus Therapeutics Inc. (FOLD)

12.475   0.285 (2.34%) 05-29 16:00
Open: 12.2 Pre. Close: 12.19
High: 12.52 Low: 11.89
Volume: 1,709,207 Market Cap: 3,214M

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 12.532 - 12.592 12.592 - 12.645
Low: 11.749 - 11.817 11.817 - 11.876
Close: 12.374 - 12.484 12.484 - 12.578

Technical analysis

as of: 2020-05-29 4:26:13 PM
Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 15.37     One year: 17.95
Support: Support1: 11.83    Support2: 11.01
Resistance: Resistance1: 13.16    Resistance2: 15.37
Pivot: 12.15
Moving Average: MA(5): 12.40     MA(20): 12.04
MA(100): 10.32     MA(250): 10.27
MACD: MACD(12,26): 0.34     Signal(9): 0.38
Stochastic oscillator: %K(14,3): 63.33     %D(3): 63.85
RSI: RSI(14): 56.34
52-week: High: 13.39  Low: 6.25  Change(%): 10.8
Average Vol(K): 3-Month: 339397  10-Days: 300042

Price, moving averages and Bollinger Bands

Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and BULLISH in mid-long term.
FOLD has closed below upper band by 31.5%. Bollinger Bands are 31.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Sat, 09 May 2020
Amicus Therapeutics Inc (FOLD) Q1 2020 Earnings Call Transcript - Motley Fool

Thu, 07 May 2020
Amicus Therapeutics (FOLD) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance

Sun, 10 May 2020
Analysts Are Updating Their Amicus Therapeutics, Inc. (NASDAQ:FOLD) Estimates After Its First-Quarter Results - Yahoo Finance

Thu, 28 May 2020
Amicus Therapeutics Inc. [FOLD] Revenue clocked in at $208.70 million, up 27.82% YTD: What’s Next? - The DBT News

Thu, 28 May 2020
Growth Myths About Amicus Therapeutics, Inc. (FOLD) You Probably Still Believe - The News Heater

Mon, 11 May 2020
Amicus Therapeutics Inc. (FOLD) Soars 3.43% on May 11 -

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Click here to get more fundamental analysis.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 258
Shares Float (M) 205
% Held by Insiders 1.10
% Held by Institutions 109.87
Shares Short (K) 34,200
Shares Short P. Month (K) 35,450

Stock Financials

EPS -1.290
EPS Est This Year -1.320
EPS Est Next Year -1.020
Book Value (p.s.) 1.560
Profit Margin -155.73
Operating Margin -142.76
Return on Assets (ttm) -24.8
Return on Equity (ttm) -76.1
Qtrly Rev. Growth 77.8
Gross Profit (p.s.) 0.622
Sales Per Share 0.810
EBITDA (p.s.) -1.114
Qtrly Earnings Growth
Operating Cash Flow (M) -280
Levered Free Cash Flow (M) -161

Stock Valuations

PE Ratio -9.67
PEG Ratio
Price to Book value 8.00
Price to Sales 15.40
Price to Cash Flow -11.49

Stock Dividends

Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2020 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.